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Background: Claspin is a nuclear protein involved in DNA replication and damage response and is a key mediator
for the S-phase checkpoint. Claspin expression is significantly high in several human solid tumors. Furthermore,
high levels of claspin have been found in cervical cancer cell lines. Nevertheless, no data are available regarding
claspin expression in cervical tissues.
Methods: In order to investigate whether claspin immunoreactivity is related to the lesion severity and High-Risk
(HR) HPV infection, we analyzed claspin expression by immunohistochemistry in a series of cervical biopsies which
represent the steps occurring during cervical carcinogenesis (normal tissues, Cervical Intraepithelial Neoplasias 1, 2
and 3, Squamous Cell Carcinomas). All patients also had a cervico-vaginal sample for HPV testing, collected
immediately before the colposcopy-guided biopsy. The HR-HPV DNA detection was performed by the HR-HPV
Hybrid Capture 2 test. HPV genotyping was performed using the Linear Array HPV Genotyping Test.
Results: Our results evidenced a constant and significant increase of the rate of claspin positivity from the normal
tissues to carcinomas (pχ2 trend< 0.0001). In fact, the normal tissues displayed either no or faint claspin
immunoreactivity, whereas a moderate/high positivity was observed in 16% of the CIN1, 76% of the CIN2, 87.5% of
the CIN3 and 93.3% of the cancers. Moreover, we found a statistically significant correlation between claspin
expression and HR-HPV infection (pχ2< 0.0001), irrespective of the genotype. Finally, we demonstrated the
feasibility of claspin immunostaining in cervical cytology.
Conclusions: Our findings indicate that in vivo claspin expression is significantly related to HR-HPV infection and
lesion grade both in histological and cytological samples. Therefore, the analysis of claspin expression could be
clinically relevant in the diagnosis of HPV-related cervical lesions, in particular when applied to cervico-vaginal
cytology. Moreover, giving information on the proliferation rate of each lesion, claspin immunostaining may
contribute to the evaluation of progression risk, thus being helpful in patient management. Nevertheless, only large
prospective studies may clarify the true clinical usefulness of claspin expression in distinguishing lesions with
different progression potential.
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Claspin is a nuclear protein involved in both DNA repli-
cation and damage response and is a key mediator for
the S-phase checkpoint. Its main function is to facilitate
phosphorylation of the effector kinase Chk1 by the sen-
sor kinase ATR in response to replication stresses [1-3].
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reproduction in any medium, provided the orreduces cell survival, likely inducing alterations in cell
cycle checkpoints and DNA repair systems [4]. These
alterations may lead to genomic instability triggering
cancer development [5,6]. However, the expression of
claspin significantly increases in several human solid
tumors such as in colon, lung, bladder and breast cancer
[7]. Despite these findings, to date no data are available
concerning claspin expression in human cervical car-
cinogenesis which represents a paradigmatic model of
cancer development. Cervical cancer, in fact, arises via a
series of well-defined intermediate lesions throughoutal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Benevolo et al. Journal of Translational Medicine 2012, 10:132 Page 2 of 8
http://www.translational-medicine.com/content/10/1/132various steps of cellular atypia and its cause, i.e. the High
Risk Human Papillomavirus (HR-HPV) infection, is well
established. The oncogenic potential of HR-HPV lies in
the two major viral oncoproteins, E6 and E7, which bind
to and modulate a number of different cellular proteins,
interfering with almost all the cellular processes and in-
ducing genomic instability and cell proliferation. Inter-
estingly, recent in vitro data showed high claspin
baseline level in cervical cancer cell lines. In addition,
the cell lines expressing the HPV-E7 oncoprotein also
showed an increased claspin turnover [8].
Therefore, in addition to viral markers, such as E6/E7
mRNA or protein detection [9,10], cellular molecules
related to cell cycle control, may be worth of investiga-
tion in cervical pathology. Several host proteins, such as
p16 and Ki67 [11-13], have been studied, possibly repre-
senting novel biomarkers which are strictly linked to the
host changes induced by HPV. Yet, none of them has
been introduced in clinical guide lines so far, although
p16 expression is currently used by many pathologists.
In the present study, we addressed the question of
whether the expression of claspin is associated to human
uterine cervix transformation in vivo and, as a conse-
quence, if it could be used as a putative biomarker of
dysplasia and/or HR-HPV infection. To this end, we
firstly analyzed claspin expression by western blotting in
a series of both HPV negative and positive non tumori-
genic and tumorigenic cell lines. Furthermore, we deter-
mined immunohistochemical claspin distribution, in
parallel with HR-HPV DNA status, in a retrospective
series of human cervical biopsies which encompass a
representative spectrum of dysplastic and neoplastic cer-
vical lesions, aiming at investigating whether claspin ex-
pression correlated with the grade of the lesions and
HR-HPV infection in vivo.
Finally, in the knowledge that identifying molecular
alterations in cytological specimens might improve the
detection of cervical lesions at higher risk of transform-
ation in both primary screening and triage settings, we
evaluated claspin distribution in a subset of available
cytological samples, including negative, low and high
grade squamous intraepithelial lesions, collected in par-
allel with the cervical biopsies.
Materials and methods
Cell lines
The human cell lines NHEK, HK-168, SiHa, CaSki, and
HeLa were used. They were kindly provided by Dr. Federico
De Marco (Regina Elena Cancer Institute, Rome, Italy).
NHEK is a HPV negative human keratinocyte diploid cell
line; HK-168 is a non tumorigenic cell line derived from
primary human keratinocytes transfected with HPV16 and
containing about 1–2 viral copies/aploid genome [14].
SiHa, CaSki and HeLa are cervical carcinoma-derived celllines (the SiHa and CaSki from squamous cancer and the
HeLa from an adenocarcinoma) containing HPV
sequences (SiHa: 1 HPV16 genome copy per cell; CaSki:
500–600 HPV16 genome copies per cell; HeLa: 10–50
HPV18 genome copies per cell).
NHEK and HK-168 were cultured in a K-SMC (Gibco,
Invitrogen, Milan, Italy) definite medium while SiHa,
CaSki and HeLa were cultured in DMEM supplemented
with 10% of fetal bovine serum and antibiotics (penicillin
100 U/mL, and streptomycin 100 μg/mL).
Western blotting
Analysis with rabbit polyclonal antibody against claspin
(Bethyl Laboratories, Montgomery, TX, USA) was per-
formed according to a published protocol [5]. Briefly,
the samples were boiled in sample buffer and separated
by SDS-PAGE. The proteins were, then, transferred to a
nitrocellulose membrane (Amersham Pharmacia Bio-
tech, Freiburg, Germany) and incubated with the pri-
mary antibody. After removing the unbound primary
antibody, the membranes were incubated with a second-
ary antibody-peroxidase conjugate (Sigma Chemical Co.,
MO, USA), processed for detection by chemilumines-
cence (Amersham), and imaged on Biomax film (Kodak,
Milan, Italy). A rabbit polyclonal antibody against Actin
(Santa Cruz Biotechnology, CA, USA) was used as a
loading control.
Histological samples
This study was reviewed by the Ethics Committee of the
Regina Elena Cancer Institute. We selected 80 cases
from the Regina Elena Cancer Institute files, which had
been collected between June 2006 and July 2009, submit-
ted to a colposcopy-guided cervical biopsy immediately
after a cervico-vaginal sampling for HPV testing. All
histological slides were independently reviewed by two
experienced pathologists and an adjudicated final diag-
nosis was established. Of the 80 formalin fixed biopsies,
9 had no relevant lesions (herein referred to as WNL:
within normal limits), 19 were diagnosed as Cervical
Intraepithelial Neoplasia (CIN) 1, 21 as CIN2, 16 as
CIN3 and 15 as invasive Squamous Cell Carcinomas
(SCC). For the purpose of our study, the WNL and
CIN1 diagnoses were referred to as CIN2-, while CIN2,
CIN3 and SCC were referred to as CIN2+. Therefore, on
the basis of this classification, we analyzed 28 CIN2- and
52 CIN2+ cases. This sample size was adequate to detect
a significant difference at 1% level with a statistical
power of 90%, according to an a priori power calculation
based on data from our laboratory regarding Ki67 re-
activity in cervical pathology (data not shown). In fact,
given that Ki67 is a well known proliferation marker
which is widely applied in solid tumors [15], we
expected a similar distribution of immunoreactivity for
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mum number of 54 patients, 27 per CIN2- group and 27
per CIN2+ group.Cytological samples
Of the 80 cervico-vaginal specimens collected in Pre-
servCyt (Hologic, Rome, Italy) for HPV testing, 19 had a
residual sample which was sufficient to obtain thin layer
slides which were adequate for both morphological and
immunocytochemical analyses. The thin layer slides
were prepared using the ThinPrep 2000 System (Holo-
gic), following the manufacturer’s instructions. Papanico-
lau slides were interpreted independently from all other
findings, and classified according to the Bethesda 2001
guidelines [16], by two experienced cytopathologists. An
adjudicated final report was established and reported as
3 Negative for Intraepithelial Lesion or Malignancy
(NILM), 7 Low-Grade Intraepithelial Lesions (L-SIL)
and 9 High-Grade Intraepithelial Lesions (H-SIL).Claspin immunostaining
The immunohistochemistry (IHC) performed to detect
claspin expression was carried out on 3 μm thick sec-
tions cut from formalin-fixed paraffin embedded blocks.
We used a monoclonal antibody which was kindly pro-
vided by Professor T. Halazonetis (University of Geneva
Switzerland), and directed against the amino-acidic resi-
dues 785–1056 of the full-length protein as previously
described [7]. Antigen retrieval was carried out pre-
treating dewaxed and rehydrated slides in a water bath
at 96 °C for 40 minutes in ethylenediamine tetracetic
acid buffer (EDTA, pH 8.0). Immunoreactivity was
revealed by means of a super sensitive streptavidin-
biotin immunoperoxidase system (Novocastra, Menar-
ini, Florence, Italy), using 3-amino-9-ethyl-carbazole as
a chromogenic substrate. Nuclear staining, independent
of intensity, was considered positive, excluding the basal
layer in which proliferating cells are physiologically
present. For each sample, we counted the positive nu-
clei in four to six selected High Power field (HPF, 400X
magnification) representative of the lesion using an
image analyzer (Eureka Interface, Menarini). A max-
imum of 200 immunoreactive nuclei/HPF were
counted. For each sample, we calculated the mean
number of the positive nuclei counted in all selected
fields, thus obtaining a single value reported as nuclei/
HPF value. For the purpose of the study, on the basis
of the nuclei/HPF value, we distinguished 4 different
categories of claspin reactivity: negative (0 or less than
1 immunoreactive nuclei/HPF), low-positive (1 to <20
immunoreactive nuclei/HPF), moderate-positive (20 to
80 immunoreactive nuclei/HPF), high-positive (more
than 80 immunoreactive nuclei/HPF).The immunocytochemical analysis of the 19 available
cervico-vaginal samples was performed following the
above described procedure, after fixing Thin-Prep slides
in 10% buffered formalin for 20 minutes followed by
water rinsing. Immunostaining was considered positive
when at least one cell showed nuclear reactivity either
among the superficial and intermediate typical cells or
among the clearly atypical cells, independently of all
other findings.HPV testing
The HR-HPV DNA detection was performed on cyto-
logical samples by the HR-HPV Hybrid Capture 2
(HC2) test (Qiagen, Milan, Italy), following the manu-
facturer’s recommendations. Before the HC2 test,
2 mL of each sample were processed using the HC2
Sample Conversion Kit (Qiagen). The HR-HPV HC2
assay detects the most common 13 HR-HPV types in
cervical cancer: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56,
58, 59 and 68. The HPV genotyping test was per-
formed by the PCR based Linear Array HPV Geno-
typing kit (Roche Diagnostics, Italy), utilizing 250 μL
of the residual liquid sample and following the manu-
facturer’s instructions. This assay is able to detect 37
high, intermediate and low risk HPV types (6, 11, 16,
18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55,
56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73,
81, 82, 83, 84, IS39 and CP6108). Only samples that
were found positive to at least one of the 13 geno-
types recognized by the HC2 test were considered to
be HPV DNA positive by PCR. Moreover, because of
the higher oncogenic potential displayed by HPV 16
and 18 types [13], we divided the positive results into
two categories: 1) presence of HPV 16 and/or 18
sequences with or without other genotypes (16/18
positive), 2) detection of HR-HPV genotypes other
than 16 and 18, as single or multiple infections (HR-
HPV positive).Statistical analyses
Data were analyzed with SPSS statistical software version
17.0. (SPSS Inc., Chicago IL, USA). The associations
between variables of interest were performed by the non-
parametric Pearson Chi-Square test and the Kruskall-
Wallis test, when appropriate. Analyses for trend were
also carried out by using the Chi-square test for trend. A
p-value< 0.05 was considered to be statistically signifi-
cant. To evaluate the sensitivity and specificity for the
presence of a CIN2+ lesion, the cases showing negative
or low claspin expression were considered as negative
whereas the cases with moderate or high claspin immu-
noreactivity were regarded to as positive.
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In vitro claspin expression
In order to investigate the correlation between claspin
expression and uterine cervix transformation, we exam-
ined the expression of claspin by western blotting both
in normal human keratinocytes (NHEK) and in a series
of cell lines that resembled cervical malignancy at differ-
ent stages of tumorigenesis (HK-168, SiHa, CaSki,
HeLa). We found no claspin expression in the normal
cell line and in the HK-168 cell line which has a basal/
parabasal keratinocyte phenotype resembling the CIN2
stage [14], while its expression was evident in SiHa,
CaSki and HeLa cervical carcinoma cell lines (Figure 1).Claspin expression in human cervical lesions
In order to investigate whether results obtained on the
cell lines could be reproduced in human cervical tissue
samples, and whether claspin expression could be linked
to the severity of the lesions, we analyzed this biomarker
by IHC (Figure 2) in a series of 9 WNL biopsies, 19
CIN1, 21 CIN2, 16 CIN3, and 15 SCC. We calculated
the mean and the median value of the claspin-positive
nuclei/HPF values within each diagnostic category
(Table 1). We found that WNL tissues and CIN1 showed
a very scanty mean positivity of less than 10 nuclei/HPF
with a median value of 0.0. In contrast, we found a mean
value of 46.8 ± 38.8 and a median of 36.5 in the CIN2
lesions, a mean value of 72.6 ± 46.7 and a median of 67.3
in the CIN3 lesions, and a mean value of 133.9 ± 75.8
and a median of 200.0 in the SCC. Therefore, the mean
and median claspin-positive nuclei/HPF values consist-
ently and significantly increased from CIN1 to SCC
(p Kruskall-Wallis <0.0001). Of interest, the minimum
claspin-positive nuclei/HPF value appeared to be inde-
pendent of the severity of the histological diagnosis,
whereas the maximum value showed a consistent in-
crease from WNL to SCC samples.
Afterwards, according to the four-score categories of
reactivity described in the Materials and MethodsFigure 1 Western blot analysis of cell lines. Western blot analysis
with a claspin specific antibody performed on NHEK (lane 1), HK-168
(lane 2), SiHa (lane 3), CaSki (lane 4), HeLa cell lines (lane 5). Actin
was used as an internal control for sample loading. Because claspin
activity is regulated by phosphorylation, the high molecular weight
band might correspond to a phosphorylated form while the low
molecular weight band might be due to protein degradation.section, we compared the proportion of the negative/low
positive and the moderate/high positive cases within
each histological category (Figure 3). The 9 WNL tissues
were mostly negative, only two cases showing low clas-
pin positivity. Conversely, we observed a moderate/high
positivity in 3 out of the 19 CIN1 lesions (15.8%), in 16
out of the 21 CIN2 lesions (76.2%), in 14 out of the 16
CIN3 lesions (87.5%), and in 14 out of the 15 SCC
(93.3%). Therefore, starting from the WNL tissues
through to carcinomas, we observed a constant and sig-
nificant increase of claspin expression (pχtrend
2 < 0.0001).
In addition, claspin showed a high sensitivity for CIN2+
lesion (84.6%), and an even higher specificity (89.3%)
(data not shown). However, due to the limited and non-
randomly selected series of cases, the accuracy indicator
values should be interpreted with caution.Correlation between claspin immunoreactivity and
HR-HPV infection
In order to investigate the correlation between claspin
expression and HR-HPV infection, we compared the
IHC findings with the HC2 results (Table 2). We
observed a statistically significant correlation between
moderate/high claspin expression and HR-HPV infection
(p(χ2) <0.0001). In fact, 46 out of the 47 moderate/high
claspin positive cases were HR-HPV positive (97.8%). In
addition, 44 out of the 46 claspin positive/HR-HPV posi-
tive cases (95.6%) were CIN2+, whereas among the 23
claspin negative/HR-HPV positive cases we found only 8
CIN2+ lesions (34.7%). Therefore, among the HR-HPV
positive cases, immunoreactivity for claspin seems to be
associated with presence of a CIN2+ lesion.
Furthermore, we performed a genotyping test in 58
out of the 69 HC2 positive cases. Overall, 3 cases
were excluded from the analysis, because they showed
positivity for one or more HPV types different from
the 13 HR-HPV types officially detected by the HC2
test, probably due to the well documented cross-
reactivity of this assay with other HPV types. All the
remaining 55 cases were positive for one or more of
the 13 HC2 HR-HPV types. In particular, as shown in
Table 3, 30 out of 55 specimens presented the HPV16
and/or 18 types (54.5%), while 25 displayed other HR
genotypes (45.5%). Comparing the distribution of clas-
pin immunostaining with the PCR findings, we found
no significant association between claspin immunor-
eactivity and HPV16/18 infection. In fact, even though
22 out of the 30 HPV 16/18 positive cases showed
moderate/high claspin immunostaining (73%), we found
a not statistically significant difference in moderate/high
immunoreactivity rate in comparison with the samples
infected by other HR-HPV genotypes (16 out of 25 cases,
64%; p = 0.65).
Figure 2 Immunohistochemical staining of cervical biopsies for claspin expression. A: CIN1 showing low immunoreactivity. B: CIN2
showing moderate immunoreactivity. C: CIN3 showing high immunoreactivity. D: Squamous Cell Carcinoma showing high immunoreactivity.
Counterstaining with haematoxylin. Magnification 20X, scale bar = 30 μm. CIN Cervical Intraepithelial Neoplasia.
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In order to verify whether claspin detection was feasible
on cervical cytology, we evaluated its expression in the
19 available cervico-vaginal samples out of the 80 corre-
sponding histological specimens tested, as specified in
the Materials and Methods section. As shown in Table 4,
despite the small number of specimens, claspin expres-
sion seems to correlate with the severity of the cellular
abnormalities. In fact, only one NILM sample was clas-
pin positive, while 4 out of the 7 L-SIL (57%) and all the
9 H-SIL (100%) showed claspin positive nuclei. More-
over, we found that all the 14 claspin immunoreactive
cases were also HC2 positive and 13 out of these had aTable 1 Distribution of claspin positive nuclei/HPF values
by histological diagnosis
Claspin-positive nuclei/HPF
Histology Mean (±SD) Median (Min-Max)
WNL (n = 9) 0.4 (±0.8) 0.0 (0.0 -1.8)
CIN1 (n = 19) 7.4 (±13.8) 0.0 (0.0 -51.5)
CIN2 (n = 21) 46.8 (±38.8) 36.5 (1.0-148.6)
CIN3 (n = 16) 72.6 (±46.7) 67.3 (2.0-159.1)
SCC (n = 15) 133.9 (±75.8) 200.0 (11.8-200.0)
p(Kruskall-Wallis)< 0.0001.
HPF, High Power Field; SD, standard deviation; WNL, Within Normal Limit; CIN,
Cervical Intraepithelial Neoplasia; SCC, Squamous Cell Carcinoma.histologically confirmed lesion (4 L-SIL: 2 CIN1 and 2
CIN2; 9 H-SIL: 6 CIN2 and 3 CIN3; data not shown). It
is worth noting that the only claspin positive NILM case
was HC2 positive. However, due to the limited number
of cytological cases analyzed we could not perform any
statistical analysis to determine whether the observed
differences were statistically significant.
Discussion
In this study, we analyzed claspin expression in a series
of tissue samples which covered the different phases ofFigure 3 Claspin immunoreactivity shown by histological
diagnosis. WNL Within Normal Limit.CIN Cervical Intraepithelial
Neoplasia.SCC Squamous Cell Carcinoma.
Table 4 Distribution of claspin expression by HR-HPV












Negative 5 (26.3) Negative 3 (60.0) 2 1 \
Positive 2 (40.0) \ 2 \
Positive14 (73.7) Negative 0 (0.0) \ \ \
Positive 14 (100) 1 4 9
HR-HPV, High Risk Human Papillomavirus; NILM, Negative for Intraepithelial
Lesion or Malignancy; L-SIL, Low Grade Squamous Intraepithelial Lesion; H-SIL,
High Grade Squamous Intraepithelial Lesion.
Table 2 Correlation between claspin expression and

















Negative 10 (30.3) 5 5 \ \ \
Positive 23 (69.7) 4 11 5 2 1
Moderate/High
47 (58.8)
Negative 1 (2.2) \ 1 \ \ \
Positive 46 (97.8) \ 2 16 14 14
p(χ2) <0.0001.
HR-HPV, High Risk Human Papillomavirus; WNL, Within Normal Limit; CIN,
Cervical Intraepithelial Neoplasia; SCC, Squamous Cell Carcinoma.
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represents an important model of tumor development
and progression. In fact, differently from the majority of
human solid tumors, its causative agent, namely the HR-
HPV, is well defined. Nevertheless, although the steps
preceding cervical cancer have been extensively studied
and are known to be linked to the active transcription of
the E6 and E7 viral oncogenes, only a few biomarkers of
active infection have been identified to date. Claspin is a
critical regulator of the ATR/Chk1 signalling axis in the
G2 DNA damage checkpoint [8] and it might represent
a novel marker of uterine cervix transformation. In fact,
it has been demonstrated that the viral oncoproteins ac-
tivate the proliferation pathway even in presence of
DNA damage, concomitantly affecting a number of cel-
lular proteins, including claspin. Therefore, claspin up-
regulation may represent a suitable marker of altered
cellular proliferation due to HR-HPV infection. In cer-
vical pathology, other putative biomarkers linked to pro-
liferation control, have been investigated, e.g., Ki67,
PCNA, minichromosome maintenance protein (MCM),
and cyclins A and E [12,13,17]. These proteins, which
are normally active during S-phase entry, are up-
regulated during HPV infection. Nevertheless, none of
these biomarkers has been validated in a clinical setting
so far. The cyclin-dependent kinase inhibitor p16INK4a,
involved in cell cycle control, has also been found over-
expressed in pre-neoplastic and neoplastic lesions of theTable 3 Association between claspin expression and HPV
genotyping in 55 HC2-positive samples
HPV genotyping Claspin expression
Negative/Low Moderate/High Total
HPV 16/18 positive* 8 (27%) 22 (73%) 30 (100%)
HR-HPV positive† 9 (36%) 16 (64%) 25 (100%)
Total 17 (31%) 38 (69%) 55 (100%)
* Presence of HPV16 and/or 18 with or without other HPV types.
† Presence of one or more HR-HPV types other than HPV16 and 18, among the
HR types included in the HC2 test.
p(χ2) = 0.65.uterine cervix as a consequence of the infection by HR-
HPV [11]. Although p16 is one of the most promising
biomarker, and is being investigated in clinical settings
[18], the immunohistochemical evaluation of p16 usually
presents a limited reproducibility due to the lack of stan-
dardized criteria for the interpretation of immunostain-
ing [19].
To our knowledge, this is the first study in which clas-
pin expression has been analyzed in histological as well
as cytological cervical specimens with the aim to estab-
lish whether this marker is related to the severity of cer-
vical lesions and to HR-HPV infection. This approach
represents the first step of the framework proposed by
Arbyn to assess the potential use of a biomarker as a
screening tool for cervical cancer [20].
When we firstly evaluated claspin level in a series of
different cell lines, we evidenced an up-regulation of the
protein only in the cervical cancer cell lines SiHa, CaSki
and HeLa. Afterwards, in human cervical tissues, we
observed a significant positive correlation between the
number of claspin immunoreactive nuclei/HPF and the
severity of the lesion. In particular, while the mini-
mum number of claspin-positive nuclei/HPF was al-
most the same in all the histological categories, the
maximum value significantly increased from normal
cervix to carcinomas. This latter value could be par-
ticularly useful in clinical practice contributing to define
the risk of progression of each lesion. In fact, despite a
marked overlap between the different entities, claspin
high expression may identify those CIN1 prone to pro-
gression. On the other hand, high grade lesions display-
ing low expression may be prone to regression.
However, only a prospective study may clarify the prog-
nostic role of claspin. In a follow up study, a parallel
analysis of p16 and claspin expression may be of inter-
est, since p16 has been proposed as a prognostic bio-
marker. Our findings are mostly in agreement with
recent data [7] showing that claspin levels are higher in
human colon, lung, bladder and breast carcinomas than
in the corresponding autologous normal tissues, even
though we did not analyze autologous normal tissues.
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further investigating whether claspin expression was
differently modulated in the dysplastic lesions that
precede the cancer. This methodological approach, to-
gether with the claspin reactivity score applied in this
study, may provide more useful biological information
to be translated into clinical practice.
Concerning the correlation between claspin and HR-
HPV infection, in our series of samples we found a
statistically significant association between the protein
expression and HR-HPV infection detected by the
HC2 test, independently of the HR-HPV genotypes.
This association might have a particular clinical value,
since the 13 HR-HPV types detected by the HC2 test
are responsible for the majority of the high grade
lesions as well as cervical carcinomas (97% and 93.6%
respectively) [21,22]. Therefore, we can hypothesize
that claspin identifies almost all the high grade lesions
and cancers. Interestingly, our study seems to evidence
a correlation between claspin positivity and the pres-
ence of a CIN2+ lesion among the HR-HPV positive
cases. There are no studies regarding the interaction
between claspin expression and HPV infection in vivo,
and only one in vitro study has been published so far
[8]. The authors provide evidence that both HPV-
positive and negative cervical cancer cell lines show
increased baseline levels of claspin. Yet, HPV16-
positive cell lines show an accelerated proteolitic turn-
over which is probably due to HPV E7 oncoprotein.
Therefore, the authors suggest that HPV16-infected
cells can also enter mitosis in the presence of unre-
paired DNA, probably overcoming the DNA damage
checkpoint control. In this case, the accumulation of
claspin attempts to restore cell cycle control reinfor-
cing the G2-M checkpoint. These findings appear to
be consistent with our results, and open the need to
delve deeper into the matter by carrying out a more
accurate investigation of the correlation between clas-
pin and HR-HPV infection.
Focusing on cervical cytology, we found that claspin
positivity was associated with HR-HPV positivity and
consistently increased with the severity of cellular abnor-
malities. Immunoreactivity was mainly found among
cases with a histologically confirmed diagnosis. These
findings, although preliminary, may have relevant clin-
ical implications, mainly in the management of HPV
positive cases. In fact, the immunocytochemical detec-
tion of this biomarker may represent a novel and useful
tool which is capable of identifying those HR-HPV infec-
tions associated to a lesion. In fact, HR-HPV testing,
despite its high sensitivity, is limited by a low specificity
in detecting high grade lesions, since the majority of
HPV infections are transient and not linked to histologi-
cally confirmed cervical dysplasia [23].Conclusions
Our findings indicate that in vivo claspin expression is
significantly related to HR-HPV infection and lesion
grade both in histological and cytological samples.
Therefore, the analysis of claspin expression could be
clinically relevant in the diagnosis of HPV-related cer-
vical lesions, in particular when applied to cervico-
vaginal cytology. Moreover, giving information on the
proliferation rate of each lesion, claspin immunostaining
may contribute to the evaluation of progression risk,
thus being helpful in patient management. Nevertheless,
only large prospective studies may clarify the true clin-
ical usefulness of claspin expression in distinguishing
lesions with different progression potential.
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